| Literature DB >> 35629680 |
Noor Ul Ain1, Shuye Wu1, Xiang Li1, Duxin Li1, Zhenqing Zhang1.
Abstract
Licorice is known as "Gan-Cao" in traditional Chinese Medicine (TCM), belonging to the genus Glycyrrhiza (Family: Fabaceae/Leguminosae). It has a long medicinal history and wide applications in China. Polysaccharides of licorice (LPs) are one of the key bioactive components. As herbal polysaccharides attracted increasing interest in the past several decades, their extraction, isolation, structural characterization, pharmacological activities, and medicinal application have been explored extensively. It is worth heeding that the method of extraction and purification effects LPs, apart from specie and origin specificity. This review evaluates the method of extraction and purification and demonstrates its performance in gaining specific composition and its structure-activity relationship, which might lead the readers to a fresh horizon for developing advanced treatment strategies. It is recently reported that the conformation of LPs plays a vital role as biopolymers, such as selenized modification, microencapsulation, nanocomposite, liposome formulation, drug/hydrogel combinations, biosensor device, and synergistic effect with a vaccine. In addition, LPs showed a good thermodynamics profile, as these properties enable them to interact with additional supramolecular interaction by chemical modifications or copolymerization. Functional polymers that are responsive to various external stimuli, such as physical, chemical, and biological signals, are a promising study topic. Thus, LPs are emerging as a new biomaterial that can enhance intended formulation along exerting its inherent medicinal effects. It is hoped that this review will provide a basis for the utilization and further developments of licorice polysaccharides in the vast medium.Entities:
Keywords: Glycyrrhiza; bio-activity; biomaterial; extraction method; licorice; modern formulation; polysaccharides; structure
Year: 2022 PMID: 35629680 PMCID: PMC9147829 DOI: 10.3390/ma15103654
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.748
Figure 1Number of research publications based on licorice polysaccharides.
Examples of extraction and purification methods.
| Method of Extraction and Solvent Used | Extraction Conditions Liquid: Material (mL/g), Temp., and Yield | Purification via | LPs Purity % | Mw | Fraction | Comments | Ref. | |
|---|---|---|---|---|---|---|---|---|
| Ningxia, China, Root | Water | 9, 1 h, 80 °C | DEAE-52 and Sephadex G-100 column chromatography | 85.23 | 10160 Da | GUPs-1 | Highest proportions of | [ |
| 84.16 | 11680 Da | GUPs-2 | Protein 6.12%, | |||||
| 83.24 | 13360 Da | GUPs-3 | High protein association 28.01%, | |||||
| Gansu, China | Water | 13, 1.42 h, 70 °C, 4.32% | DEAE-52 and Sephadex G-100 column chromatography | 4.513 × 103 Da | GPs1 | Mainly consist of | [ | |
| 1.378 × 105 Da | GPs2 | |||||||
| 2.084 × 105 Da | GPs3 | Mainly consist of | ||||||
| Gansu, China | Water | 11, 2.33 h, 80 °C, 22.31% | GP | Surface Response Method applied optimized extraction process. Gives high yield. | [ | |||
| Xinjiang, China | Water | 15, 2 h, 99 °C, 16.41% | DEAE cellulose-32 column chromatography and sephadex G-100 column | GUPII | [ | |||
| Xinjiang, China | Water | 30, 2 h, 90 °C, 8.1% | GUP | Protein 10.07%, | [ | |||
| Zhenjiang, China. | Water | 20, 3.5 h, 90 °C, 5.67% | DEAE-52 column chromatography and SephadexG-200 gel column chromatography | 98.58 | 294373 Da | GUP1 | High proportion of | [ |
| 98.39 | 17416 Da | GUP2 | Highest proportion of | |||||
| Karakalpakstan, Uzbekistan | Water | 30, 3 h, 90 90 °C | DEAE-Cellulose-52 column and Sephadex G-100 column | 98.49 | 3.87 × 105 Da | GPN | [ | |
| Xinjiang, China, | Water | 15, 2 h, 120 °C | DEAE-Sepharose fast flow column chromatography | 87.46 | GP1 | [ | ||
| 74.47 | GP2 | |||||||
| 52.59 | GP3 | |||||||
| Xinjiang, China, | Water | 30, 2 h, 90 °C, 8.45% | GGP | Protein 8.73%, | [ | |||
| Hilden, Germany | Water | 5, [20 h, 8 °C] ×3, 2.5% | DEAE Sephacel column | 81 | RPS | Protein 18.5%, | [ | |
| Aksu, Xinjiang China. | Alkaline | n.m, 2 h, 50 °C | DEAE-cellulose and Sephadex G-150 | 93.29 | 2.89 × 106 Da | AGP | Highest proportion of | [ |
| Aksu, Xinjiang | Water | 3, 2 h, 80 °C, 4.315 | HPLC and Sephadex G-200 | n.m | 1.96 × 106 Da | GIBP | This fraction contained protein 8.14%, | [ |
| n.m, | Water | 10, 6 h, 100 °C, 0.21 | DEAE Sepharose Fast Flow and Sepharose CL-6B gel filtration chromatography | 94.05 | 3.3 × 105 Da | GIP1 | Highest proportion of | [ |
| Aksu, Xinjiang China. | Water | 3 h, 100 °C | DEAE-52 ion exchange chromatographic column, Sepharose Cl -6B Agarose gel column | 2 × 106 Da | GiP2 | Highest proportion of | [ | |
| 2.1 × 107 Da | GiP3 | Highest proportion of | [ | |||||
| n.m, | Water | 21, 1.38 h, 93 °C, 10.48 | DEAE-52 and Sephadex G-75 column chromatography | GPS | Optimized method for extraction | [ | ||
| n.m, | Water, | 70, 0.5 h, 90 °C, 7.72% | DEAE-52 and Sephadex G-75 column chromatography | 92.685 | GPS | Each part needs specific conditions | [ | |
| n.m, | Water, | 40, 0.3 h, 80 °C, 7.49% | 86.424 | |||||
| Xinjiang China, seed | Water | 30, 2 h, 90 °C, 7.83 | GIP | Protein 7.4%, | [ | |||
n.m: not mentioned. TH: triple helix. * is Highest Proportion of Monosaccharides in Molar Ratio.
Figure 2Carbohydrate predictable regions in 1H and 13C NMR spectra chemical shift assignments [60,61,62].
1H and 13C NMR chemical shift assignments of LPs.
| Polysaccharide | Conditions Mentioned in the Literature | Anomeric H (ppm) | Anomeric C (ppm) | Residue | Ref. |
|---|---|---|---|---|---|
| UA | Ref. standard: 2,2-dimethyl-2-silapentan-5-sulfonat, temp. 303 K | 100.26 | α-D-galactopyranosyluronic acid | [ | |
| 101.21 | α-L-rhamnopyranose | ||||
| 105.31 | β-D-glucopyranosyluronic acid | ||||
| 105.87 | β-D-galactopyranose | ||||
| 110.16 | α-L-arabinofuranose | ||||
| 111.94 | α-L-arabinofuranose | ||||
| Gi-A1 | 60~70 mg + 0.5 mL D2O, temp.301.1 K | 108.25 | α-L-Araf-(1 | [ | |
| 107. 5 | |||||
| 100.4 | α-D-Glcp-(1 | ||||
| 100.34 | |||||
| 100.49 | |||||
| 99.37 | α-D-Galp- (1 | ||||
| Gi-A3 | 5.09 | 107.1 | α-L-Araf-(1 | ||
| 5.25 | 108.2 | ||||
| 5.36 | 100.6 | α-D-Galp-(1 | |||
| 5.4 | 100.5 | ||||
| 4.97 | 99.32 | ||||
| Gi-B1 | 5.17 | 101.1 | α-D-GalpA-(1 | ||
| 5.15 | 100.2 | ||||
| 5.24 | 99.7 | ||||
| 5.22 | 99.7 | ||||
| 5.11 | 107.6 | α-L-Araf (1 | |||
| 5.08 | 108.2 | ||||
| 4.98 | 96.7 | α-D-Galp-(1 | |||
| 4.96 | 96.8 | ||||
| GUPII | 40 mg + 0.5 mL D2O, temp. 333 K, 600 MHz | 4.98 | 107.43 | α-L-Araf-(1 | [ |
| 4.92 | 107.32 | 3)-α-L-Rha-(1 | |||
| 5.21 | 99.82 | 3)-α-D-Galp-(1 | |||
| 5.92 | 99.62 | α-D-Xylp-(1 | |||
| 4.51 | 95.62 | ||||
| GUPIII | 4.98 | 107.37 | α-L-Araf-(1 | ||
| 4.96 | 107.31 | 3)-α-L-Rha-(1 | |||
| AGP | 30 mg AGP + 0.5 mL D2O, temp. 298 K, 400 MHz | 5.05 | 107.63 | [ | |
| 4.59 | 106.53 | ||||
| 5.11 | 107.03 | ||||
| 5.36 | 101.77 | ||||
| 5.21 | 98.72 | ||||
| 4.94 | 97.70 | ||||
| 5.14 | 99.76 | ||||
| GIBP | 40 mg + 0.6 mL, 298 K, 400 MHz | 5.35 | 99.82 | [ | |
| 4.91 | 99.85 | ||||
| 5.06 | 99.14 | ||||
| 5.20 | 109.43 | ||||
| 4.59 | 104.06 | α-D-Gal-(1 | |||
| 4.44 | 103.09 | ||||
| 5.11 | 107.04 | β-D-Gal-(1 | |||
| 5.04 | 107.54 | ||||
| 5.17 | 92.05 | ||||
| 4.58 | 95.93 | ||||
| GPN | 40 mg + 0.6 mL, 298 K, 400 MHz | 5.39 | 100.76 | →4)-α-Glcp-(1→ | [ |
| 5.40 | 100.89 | →4)-α-Glcp-(1→ | |||
| 4.97 | 99.74 | → 6, 4)-α-Glcp-(1→ | |||
| 4.80 | 100.81 | →1, 3)-α-Glcp(6→ | |||
| 4.65 | 96.92 | β-Glcp-(1→ | |||
| Gu-1 | 5% sample in deuterated dimethylsulfoxide, 125.7 MHz | 99.29 | α-D-galactopyranosyl | [ | |
| 101.74 | 4-O-β-D-mannopyranosyl | ||||
| 100.98 | 4,6-Di-O-β-D-mannopyranosyl | ||||
| 93.50 | α -D-galactopyranoses | ||||
| 94.90 | β-D-mannopyranosyl |
Medicinal properties of licorice polysaccharides and mechanism of action.
| Species | Experimental | Model | Mechanism | Concentration | Ref. |
|---|---|---|---|---|---|
| Acute hyperuricemia was induced by oral administration of hypoxanthine and intraperitoneal injection of potassium oxonate. | In vivo | Inhibition of XO. | 300 mg/kg | [ | |
| Scavenging •OH, •O2−, 1,1- DPPH• on oil. | In vitro | Antioxidant. | [ | ||
| Mononuclear cells isolated from cord blood collected under axenic condition. | In vitro | Immunomodulator effect on differentiation, maturation, and immune activity of DC. | 400 µg/mL | [ | |
| Growth performance, immune organ indexes, immunologic functions. | In vivo | 100 mg/mL | [ | ||
| Myotube atrophy model of C2C12 cells based on co-culture system of C26 colon cancer cellsand RAW264. 7 macrophages. | In vitro | Down-reg. of p-STAT3/STAT3 via inhibiting RAW264. 7 macrophages. | 2 mg/mL | [ | |
| 36 COPD cases of phlegm dampness. | In vivo | Immune regulation. | [ | ||
| Suckling piglets’ diet. | In vivo | 2.5% LPs in diet | [ | ||
| Production of TNF-α and the expression of TNF-α mRNA using BALB/C mice. | In vivo | 200 µg/mL | [ | ||
| Rat liver tumor. | In vivo | 30 mg/kg | [ | ||
| Pentylenetetrazol kindled epileptic rats. | In vivo | Down-reg. of P2 × 7 receptor and NF-кB protein expression in hippocampus, | 50 mg/kg | [ | |
| Fresh human blood. | In vitro | Promote γδ T cells, | 100 mg/L | [ | |
| Colon microorganism of broilers. | In vivo | Proliferation of bifidobacteria and lactobacillus, inhibition of Escherichia coli and Salmonella. | 1000 mg/kg | [ | |
| Mouse peritoneal macrophages. | In vivo | Expression of iNOS mRNA and Generation of NO and iNOS | 400 µg/mL | [ | |
| Immunized FMD Mouse spleen. | In vivo | Indirect activate DNA polymerase, | 100 mg/kg (1–2 × 105 Da) | [ | |
| In feed, broilers body weight. | In vivo | 900 mg/kg | [ | ||
| CT 26 tumor-bearing mice immune organ indices, immune cell population, and serum cytokine levels. | In vivo | Immunomodulator activity via activation of CD4+ and CD8+ immune cells, increasing IL 2, IL 6, IL 7 levels. | 500 mg/kg (under 1 × 104 Da) | [ | |
| TCDD-induced hepatotoxicity in Jian carp fish. | In vivo | 1 g/kg | [ | ||
| DPPH•, ABTS+•, and •OH, scavenging essay. | In vitro | Antioxidant. | 0.186 mg/mL | [ | |
| Citric acid-induced cough efforts in guinea pigs. | In vivo | Antitussive action (immunomodulator). | 50 mg/kg | [ | |
| Kunming mice fed high-fat diet. | In vivo | 100 mg/kg | [ | ||
| Human hepatocellular carcinoma cells and its mechanism via apoptosis assay, real-time PCR, and Western blot analysis on imprinting control region mice. | In vivo | Tumor suppressor through influencing P53/PI3K/AKT pathway. | 1250 μg/mL | [ | |
| DPPH•, •OH, and mouse splenocyte. | In vitro | Antioxidant, | 100 µg/mL | [ | |
| Apoptosis of human oral cancer SCC-25 cell line. | In vitro | Down-reg. of Blc-2, up-reg. of Bax, release of cytochrome c, activate the initiator caspase-9 and effector caspases-3, cleaves PARP. | 200 μg/mL | [ | |
| α-glucosidase (1 U/mL), DPPH•, •OH, •O2−, ABTS•+. | In vitro | Inhibition of α-glucosidase and antioxidant. | 64.77% α-glucosidase inhibits at 6 mg/mL, antioxidant at 3 mg/mL | [ |
Note: Up-reg.: Up-regulation; Down-reg.: Down-regulation; ↑: increase; ↓: decrease; →: leads to. Abbreviations: ABTS: 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); AHR2: Aryl hydrocarbon receptor 2; AKP: Alkaline phosphatase; Alb: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ARNT2: Aryl hydrocarbon receptor nuclear translocator 2; Blc-2: B-cell lymphoma 2; Bax: Blc-2 Associated X-protein; CD4+/CD8+: Cluster of differentiation; CAT: Catalase; COPD: Chronic Obstructive Pulmonary Disease; DC: Dentritic cells; •DPPH: 1,1-diphenyl-2-picrylhydrazyl; FMD: Foot and Mouth Disease; GPx or GSH-Px: Glutathione Peroxidase; IGF-1: Insulin like Growth Factor-1; Ig A/G/M: Immunoglobulin A/G/M; iNOS: induced Nitric Oxide synthase; IL: Interleukins; LDH: Lactate dehydrogenase; MDA: Malondialdehyde; NF-кB: Nuclear Factor-kappa-B cell; NK: Natural killer; PI3K/AKT: Phosphatidylinositol 3-kinase; PARP: poly(ADP-ribose) polymerase; p-STAT3/STAT3: phosphorylated-Signal Transducer and Activator of Transcription 3; SOD: Superoxide dismutase; TNF-α: Tumor Necrosis Factor-alpha; γδ T: Gamma delta T cells; TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin; T-AOC: Total antioxidant capacity; XO: Xanthine oxidase.
Figure 3Triple helix structure of LPs. (a) SEM micrographs of polysaccharides from the seeds of the [A] ural, [B] inflata, and [C] glabra licorice at 10,000× magnification [42], (b) proposed structure of polysaccharide GIBP from inflata licorice [47], (c) FAM micrographs of the polysaccharide from the root of ural licorice [B] angular view, and [C and D] section analysis [94].
Figure 4Some methods of formulation using licorice polysaccharides. Formulation method, quantities and conditions are retrieved from: (A): selenium modification [101]; (B): LPs microencapsulation [40]; (C): LPs nanocomposite [105]; (D): LPs based hydrogel [106]; (E): LPs liposome [107]; (F): LPs nanofiber [109]; (G): LPs based biosensor [111].
Figure 5Corresponding results LPs-based formulations. (a) LPs based microencapsulation (speculated diagram) and results A, B, and C obtained from [40], (b) LPs based nanocomposite film (diagrammatic concept adopted), and the experimental results obtained from [105], (c) LPs based hydrogel (speculated diagram) and result obtained from [106] (d) LPs based Liposome (speculated diagram), and experimental result obtained from [107], (e) LPs based electrospun nanofiber (speculated diagram), and experimental result obtained from [109], (f) LPs based biosensor (diagrammatic concept adopted), and results obtained from [111]; TH; diagrammatic concept of triple helix structure of LPs.